Major Gastrointestinal Disorders and Peritoneal Infections DRG

DRG 373 encompasses major gastrointestinal disorders and peritoneal infections without Complication or Comorbidity or Major Complication or Comorbidity, covering serious intra-abdominal conditions that do not meet higher severity criteria. This matters for inpatient reimbursement because Diagnosis-Related Group assignment drives Medicare payment by reflecting the expected resource intensity for these noncomplicated but significant clinical scenarios.

DRG 373 Overview

DRG 373 covers major gastrointestinal disorders and peritoneal infections without Complication or Comorbidity or Major Complication or Comorbidity. This group includes cases such as noncomplicated gastrointestinal perforations, severe infections of the peritoneum without additional coded complications, and other significant intra-abdominal conditions that do not meet higher severity tiers. It matters for Medicare reimbursement because it establishes the inpatient payment relative to resource use for these serious but noncomplicated presentations. Accurate coding and documentation determine assignment to this Diagnosis-Related Group and the associated payment weight.

Acute surgical intervention trials: randomized or pragmatic studies comparing timing, technique, or perioperative protocols for patients presenting with acute major gastrointestinal disorders (such as complicated diverticulitis, perforated viscus, or severe intra-abdominal infections) who require urgent operative or interventional management. These studies enroll hospitalized adults at the time of acute presentation and evaluate outcomes like time to source control, complication rates, length of stay, and short-term mortality. Findings inform surgeons and hospitalists about best practices to reduce in-hospital morbidity, optimize resource use, and potentially shorten costly inpatient stays for DRG 373 patients.
Comparative effectiveness studies of nonoperative versus operative management in complicated GI disease: observational cohorts or randomized trials assessing conservative medical therapy (antibiotics, drainage, bowel rest) versus early surgery for subsets of major GI disorders without major comorbid complications. These studies focus on patients stable enough for trial enrollment but at risk for progression, measuring readmission rates, need for delayed surgery, health resource utilization, and patient-centered outcomes such as functional recovery. Results help payers and clinicians determine which pathways reduce total cost of care and unnecessary procedures while maintaining safe outcomes for this DRG population.
Post-discharge outcomes and care-transition research: longitudinal studies and quality-improvement trials that follow patients discharged after hospitalization for major GI disorders and peritoneal infections to evaluate readmissions, post-acute care needs, outpatient complication surveillance, and adherence to secondary prevention strategies. Populations include medical and surgical survivors from index admissions, with emphasis on identifying predictors of early readmission and tailoring follow-up intensity (e.g., early clinic visits, home health, or targeted education). This research is relevant for hospitals and payers seeking to lower 30-day readmission penalties, allocate post-acute services efficiently, and improve long-term functional outcomes for patients classified under DRG 373.

Acute surgical intervention trials: randomized or pragmatic studies comparing timing, technique, or perioperative protocols for patients presenting with acute major gastrointestinal disorders (such as complicated diverticulitis, perforated viscus, or severe intra-abdominal infections) who require urgent operative or interventional management. These studies enroll hospitalized adults at the time of acute presentation and evaluate outcomes like time to source control, complication rates, length of stay, and short-term mortality. Findings inform surgeons and hospitalists about best practices to reduce in-hospital morbidity, optimize resource use, and potentially shorten costly inpatient stays for DRG 373 patients.
Comparative effectiveness studies of nonoperative versus operative management in complicated GI disease: observational cohorts or randomized trials assessing conservative medical therapy (antibiotics, drainage, bowel rest) versus early surgery for subsets of major GI disorders without major comorbid complications. These studies focus on patients stable enough for trial enrollment but at risk for progression, measuring readmission rates, need for delayed surgery, health resource utilization, and patient-centered outcomes such as functional recovery. Results help payers and clinicians determine which pathways reduce total cost of care and unnecessary procedures while maintaining safe outcomes for this DRG population.
Post-discharge outcomes and care-transition research: longitudinal studies and quality-improvement trials that follow patients discharged after hospitalization for major GI disorders and peritoneal infections to evaluate readmissions, post-acute care needs, outpatient complication surveillance, and adherence to secondary prevention strategies. Populations include medical and surgical survivors from index admissions, with emphasis on identifying predictors of early readmission and tailoring follow-up intensity (e.g., early clinic visits, home health, or targeted education). This research is relevant for hospitals and payers seeking to lower 30-day readmission penalties, allocate post-acute services efficiently, and improve long-term functional outcomes for patients classified under DRG 373.

OpenPayer

Summary & Overview

Major Gastrointestinal Disorders and Peritoneal Infections without CC/MCC: Inpatient Reimbursement Overview

DRG 373 Overview

Clinical Trials

Related Codes

Clinical Trials

Related Codes